Neueste

  • IR Chain Digital Assets Limited(IR Chain) and MASEx signed a Memorandum of Understanding (MOU) - committing collaboration in Digital Currency, Blockchain and related technology fields

    After a rigorous review process, IR Chain Digital Assets Limited’s token has successfully been approved for listing on MAS Capital Universal Exchange (MASEx). Today, Mr. Aaron Chan, CEO of IR Chain Digital Assets Ltd, and Mr. Aaron Tsai, Founder and Chief Capitalist of MAS Capital Inc. and MASEx, signed a Memorandum of Understanding (MOU) online, underscores the collaboration in Digital Currency,
  • The W World Corp. Plans to be Listed on NASDAQ

    W World Corp., a biopharmaceutical company, announces its intention to get listed on NASDAQ on 2020/2021, opening speech by Professor Dr. OUDOM, Chairman of the W World Corp, June 28, 2020 at 0:00 a.m., New York.
  • Www.acfx.com is acquired by the heavy investments of Arab Capital Group

    Recently, a major event in the domain name circle has occurred in Arab Capital Group: it has invested heavily in the acquisition of the fine domain name www.acfx.com, which has not yet been activated.
  • ACE Artificial Intelligence Blockchain Innovation Disrupts the Industry

    The market currently lacks a common platform to unite artificial intelligence development efforts. Many enterprises have invested huge capital for the procurement and maintenance of high-performance computing hardware and data networks. AI products also face increasing cost after its launch due to the growing number of users and operational tasks. AI firms require access to data to meet user searc
  • Gunfire Reborn, a FPS+Roguelite game, is on Steam “Top Sellers”

    Recently, FPS+Roguelite game Gunfire Reborn developed by Duoyi(Hong Kong) Interactive starts Early Access on Steam. Upon release, it receives much attention. It is not only on Steam “Featured & Recommended” list but also on Steam Weekly Top Sellers (05/31-06/07).
  • AML Bitcoin to be listed on LBank

    AML BitCoin is being designed by the NAC Foundation. Based on how blockchain technology has evolved in the last few years, the AML BitCoin team was not able to utilize all of the AtenCoin source code is having to rebuild. The cryptocurrency will have built in KYC/AML, anti-theft and anti-criminal features, as well as biometric identification built into the platform. This will enable it to be used
  • Shakespeare's fund equities token——BYXZ

    ​ The only sketching of William Shakespeare, which is anchored to be worth 4 billion dollars, has been stored more than 400 hundred years in the world. Enjoy the complete copyright of the sketching, move with the times, promote the super value of the industry!
  • Embracing its second anniversary, Contact Hainan sets sail with the positive wind

    The CPC Central Committee and the State Council issued the Overall- Plan for the Construction of Hainan Free Trade Port on June 1, 2020, aiming to develop Hainan Island a globally-influential high-level free trade port by liberalizing and facilitating Hainan’s trade, investment and cross-border flow of funds, etc.
  • TELEVISION NEWS ANCHOR SPEAKS OUT AGAINST MISLEADING REPORTING, DOUBLE STANDARDS

    Breaking news coverage across television networks showing recent brutal responses by U.S. law enforcement agencies against mainly peaceful demonstrators was just one of the reasons that Canadian television news anchor and documentary expert, Elissa Lansdell, felt it right to speak out last week. Elissa, a veteran interviewer of Hollywood and musical legends, also has a special passion for politics
  • Top companies choose Zhejiang,China

    ​ "As a member of our community, we always try the best to provide more support at such a special time." This is an official voice from Chevron China, which recently announced a donation of 2 million RMB to the China Women's Development Foundation to assist China in the fight against the epidemic.

Link

Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes

05-22    

Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celartics research team, demonstrate that using the proprietary engineered DC technology by targeting nucleoprotein (NP) of COVID-19, NP-specific cytotoxic CD8+ T cells from naive T lymphocytes can be efficiently induced and massively expanded in culture. The antigen-loaded DCs and viral antigen-specific T cells have great potentials in preventing viral infection and in controlling progression of virus-associated diseases, respectively.

Dendritic cells are the most potent professional antigen-presenting cells that can engulf and process viral or tumor antigens. Once DCs are loaded with viral antigen and become activated, they acquire the ability to educate naïve T lymphocytes, promoting these T cells to differentiate into antigen-specific cytotoxic T cells that can fight virus. Primary blood DCs constitute 1% of immune cells in peripheral blood and are not able to grow in culture. Manufacturing clinical grade DC with the conventional DC method, therefore, needs quite large amount of blood and is very costly, limiting DC’s application as a preventive vaccine against viral infection. To overcome various technical hurdles associated with the conventional DC method, Celartics Biopharma has developed an innovative engineered DC technology, which enables primary blood DCs from a few milliliters of peripheral blood to grow in culture, generating large amounts of highly activated DCs suitable for multiple clinical applications. These engineered DCs exhibit vastly improved antigen-loading capability and efficient lymphoid tissue homing ability due to high expression of the chemokine receptor, CCR7. In addition, the manufacturing cost for generating engineered DCs is significantly reduced. “The engineered DCs are safe to use, as demonstrated in animal studies and pilot clinical trial in cancer immunotherapy”, said Yang Yu, CEO of Celartics Biopharma

Current vaccine strategies for COVID-19 include mRNA vaccine, DNA vaccine, adenovirus vector-based vaccine and inactivated virus vaccine, with the goal of generating neutralizing antibody that reacts to Spike, the viral surface protein of COVID-19. The neutralizing antibody blocks entry of virus to host cells through ACE2 receptor. Accumulating evidences have suggested that developing permanent immunity remains challenging, exclusively by targeting heavily glycosylated Spike protein or rapidly mutating viral surface proteins such as influenza HA. Differing from these vaccine strategies, the engineered DCs are designed to empower T cells to fight virus. DC-educated T cells recognize viral antigenic peptides complexed with HLA molecules on the surface of virus-harboring host cells and launch subsequent attack to eliminate virus. Furthermore, a given viral protein in host cells is processed into multiple antigenic peptides that are bound to distinct HLA molecules, this provides many targets for antigen-specific T cells to attack. Unlike Spike protein, the NP protein of COVID-19 is less likely to mutate and also share 91% amino acid sequence homology with the counterpart of SARS virus. “The Cov-DCVax is designed to develop long-lasting protective immunity in human to fight both COVID-19 and SARS viruses”, said Yang Yu.

In last February, Celartics Biopharma announced the development of Human Dendritic Cell and Data Repository (HDCR), in order to meet urgent demands in fighting deadly virus outbreak and cancer. HDCR prepares human blood dendritic cells from healthy individuals in GMP facility, coupled with data analysis covering immunophenotyping and HLA typing. These engineered DCs are stored in liquid nitrogen and are readily available when needed, in supporting cell-based vaccination or immunotherapy. HDCR also serves as the platform technology provider to research institutions and pharmaceutical industries. The ultimate goal of HDCR is to bring in a feasibility of dendritic cells as a new form of preventive vaccines for rapidly evolving viruses. The Cov-DCVax vaccine is intended for generating long-lasting protective immunity in high risk individuals, while the viral antigen-specific T cells provide immediate therapeutic protection in controlling the progression of COVID-19-associated disease. "The current research progress and patent application enhance the spectrum of possible collaborators and partners. We are delighted that our scientific team has made solid progress in developing such unique Cov-DCVax vaccine, which may potentially yield benefits useful to high risk population, considering current global impact and severity of COVID-19 pandemic", said Yang Yu, CEO of Celartics Biopharma.


About Celartics Biopharma, Inc. Celartics Biopharma is a biotechnology company, located at Dongsheng International Science Park, Beijing. The company focuses on developing innovative cell-based immunotherapies for human cancer and viral diseases. The Company seeks rapidly advancing these technologies through pre-clinical and Phase I and II clinical trials, centering on DC therapeutic vaccine and adoptive T cell transfer therapies for treating solid cancer and leukemia. The company also seeks potential collaborators and partners for joint development through the proprietary technology platforms.

Ph.D., Chief Technology Officer, Celartics Biopharma, Inc.

Company :Celartics Biopharma Inc., Ltd.  

Contact: Huan Zhang,

Phone:010-6295 5880

Email: lily@celartics.com

Web:http://www.celartics.com/


Haftungsausschluss: Dieser Artikel wurde aus anderen Medien reproduziert. Der Zweck des Nachdrucks besteht darin, mehr Informationen zu vermitteln. Dies bedeutet nicht, dass diese Website ihren Ansichten zustimmt und für ihre Authentizität verantwortlich ist und keine rechtliche Verantwortung trägt. Alle Ressourcen auf dieser Website werden im Internet gesammelt. Der Zweck des Teilens dient nur dem Lernen und Nachschlagen aller. Wenn eine Verletzung des Urheberrechts oder des geistigen Eigentums vorliegt, hinterlassen Sie uns bitte eine Nachricht.
Zurück nach oben
© Copyright 2006-2020 tomsnews.de      Kontaktieren Sie Uns   SiteMap